방사선생물학

본문글자크기
  • [Transl Oncol.] PSP1, a Phosphatidylserine-Recognizing Peptide, Is Useful for Visualizing Radiation-Induced Apoptosis in Colorectal Cancer In Vitro and In Vivo.

    울산의대 / 배상문, 명승재*, 김상엽*

  • 출처
    Transl Oncol.
  • 등재일
    2018 Aug
  • 저널이슈번호
    11(4):1044-1052. doi: 10.1016/j.tranon.2018.06.008. Epub 2018 Jul 5.
  • 내용

    바로가기  >

    Abstract
    Accurate and timely visualization of apoptotic status in response to radiation is necessary for deciding whether to continue radiation or change to another mode of treatment. This is especially critical in patients with colorectal cancer, which requires a delicate combination of surgery, radiation, and chemotherapy in order to achieve optimal outcome. In this study, we investigated the potential of phosphatidylserine-recognizing peptide 1 (PSP1) as an apoptosis-targeting probe, which identifies phosphatidylserine on cell surfaces. We first screened colon cancer cell lines for their sensitivity to radiation and selected two cell lines: HCT116 and HT29. Cell binding assay using fluorescence-activated cell sorting and optical imaging showed that HCT116 cells had better binding to PSP1 than HT29 cells. Thus, mouse xenograft model using HCT116 cells was generated and was topically irradiated with either single or fractionated dose of radiation followed by systemic administration of PSP1 for subsequent molecular optical imaging. We confirmed that the PSP1 probe was selectively bound to apoptosis-induced tumor in a radiation dose-dependent manner. We also observed that fractionated radiation regimen, which is recently being used in clinical situation, was more effective in inducing tumor apoptosis than corresponding single-dose radiation treatment. We then evaluated the correlation between tumor targeting of PSP1 and suppression effect of tumor development and found that tumor volume and fluorescence intensity were correlated before (correlation coefficient r2 = 0.534) and after (r2 = 0.848) radiation therapy. Our study shows that PSP1 peptide is an efficient index probe for deciding "go or no-go" for radiation therapy in colorectal cancer.

     


    Author information

    Bae SM1, Park SJ2, Choi M3, Song M4, Cho YE1, Do EJ1, Ryu YM1, Park S1, Lee BH5, Lee SW6, Hwang SW7, Park SH7, Yang DH7, Ye BD7, Byeon JS7, Yang SK7, Joo J8, Kim SY9, Myung SJ10.
    1
    Asan Institute for Life Science, Asan Medical Center, University of Ulsan College of medicine, Seoul, Republic of Korea.
    2
    Asan Institute for Life Science, Asan Medical Center, University of Ulsan College of medicine, Seoul, Republic of Korea; Department of Internal Medicine and Institute of Gastroenterology, Yonsei University College of medicine, Seoul, Republic of Korea.
    3
    Department of Dermatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
    4
    Department of Life and Nanopharmaceutical Science, Kyung Hee University, Seoul, Republic of Korea.
    5
    Department of Biochemistry and Cell Biology, Kyungpook National University School of Medicine, Daegu, Republic of Korea.
    6
    Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
    7
    Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
    8
    Biomedical Engineering Research Center, Asan Institute for Life Sciences, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea; Department of Convergence Medicine, University of Ulsan College of Medicine, Seoul, Republic of Korea.
    9
    Asan Institute for Life Science, Asan Medical Center, University of Ulsan College of medicine, Seoul, Republic of Korea; Department of Convergence Medicine, University of Ulsan College of Medicine, Seoul, Republic of Korea. Electronic address: sykim3yk@amc.seoul.kr.
    10
    Asan Institute for Life Science, Asan Medical Center, University of Ulsan College of medicine, Seoul, Republic of Korea; Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea; Department of Convergence Medicine, University of Ulsan College of Medicine, Seoul, Republic of Korea. Electronic address: sjmyung@amc.seoul.kr.

  • 덧글달기
    덧글달기
       IP : 44.199.225.221

    등록